Hangzhou Fuyue Yize Equity Investment Partnership Enterprise (Limited Partnership) signed a share transfer agreement to acquire a 20% stake in Wisdom Pharmaceutical Co., Ltd. from Hunan Jingfeng Pharmaceutical Co.,Ltd. for approximately CNY 160 million.
September 11, 2020
Share
Hangzhou Fuyue Yize Equity Investment Partnership Enterprise (Limited Partnership) signed a share transfer agreement to acquire a 20% stake in Wisdom Pharmaceutical Co., Ltd. from Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) for approximately CNY 160 million on September 11, 2020. For the year ending December 31, 2019, Wisdom Pharmaceutical reported total assets worth CNY 461.31 million, net assets worth CNY 341.83 million, revenues worth CNY 304.44 million, operating profit worth CNY 50.67 million and net profit worth CNY 44.99 million. The transaction has been approved in the 23rd Meeting of Hunan Jingfeng Pharmaceutical’s 7th Directorate.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.
Hangzhou Fuyue Yize Equity Investment Partnership Enterprise (Limited Partnership) signed a share transfer agreement to acquire a 20% stake in Wisdom Pharmaceutical Co., Ltd. from Hunan Jingfeng Pharmaceutical Co.,Ltd. for approximately CNY 160 million.
HUNAN JINGFENG PHARMACEUTICAL CO.,LTD. 
